Get the Stockscreener App
5.58
9.12%
-0.56
After Hours:
5.85
0.27
+4.84%
Oric Pharmaceuticals Inc stock is traded at $5.58, with a volume of 1.97M.
It is down -9.12% in the last 24 hours and down -30.51% over the past month.
See More
Previous Close:
$6.14
Open:
$5.89
24h Volume:
1.97M
Relative Volume:
2.03
Market Cap:
$446.76M
Revenue:
-
Net Income/Loss:
$-119.87M
P/E Ratio:
-3.0829
EPS:
-1.81
Net Cash Flow:
$-109.90M
1W Performance:
-24.29%
1M Performance:
-30.51%
6M Performance:
-45.56%
1Y Performance:
-59.42%
1-Day Range:
$5.53
$5.89
1-Week Range:
$5.53
$7.34
52-Week Range:
$5.53
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
5.58 | 446.76M | 0 | -119.87M | -109.90M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Oncology Pioneer ORIC Sets Stage for 2 Major Healthcare Conference Appearances - Stock Titan
Analysts Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - Defense World
Swiss National Bank Has $504,000 Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - MarketBeat
Charles Schwab Investment Management Inc. Purchases 7,726 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC stock touches 52-week low at $6.31 amid market challenges By Investing.com - Investing.com South Africa
ORIC stock touches 52-week low at $6.31 amid market challenges - Investing.com Australia
PNC Financial Services Group Inc. Buys 2,520 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical - GlobeNewswire
Breakthrough: Novel Prostate Cancer Drug Demonstrates Powerful Two-Pronged Attack Strategy - Stock Titan
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9%Time to Sell? - MarketBeat
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance
Wedbush Reaffirms Outperform Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9% – Here’s What Happened - Defense World
(ORIC) Investment Report - news.stocktradersdaily.com
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Victory Capital Management Inc. - Defense World
Oric Pharmaceuticals Expands Equity Incentive Plan for Growth - TipRanks
(ORIC) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC's Latest Employee Stock Grants: Key Details on Compensation Package - StockTitan
Rhumbline Advisers Purchases 4,072 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
ORIC Pharmaceuticals (ORIC) Projected to Post Earnings on Monday - MarketBeat
ORIC Pharmaceuticals Reports Progress in Cancer Trials - TipRanks
Wedbush Expects Increased Earnings for ORIC Pharmaceuticals - MarketBeat
ORIC Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% After Analyst Upgrade - MarketBeat
(ORIC) Investment Analysis and Advice - news.stocktradersdaily.com
ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 - Defense World
ORIC Pharmaceuticals’ (ORIC) Buy Rating Reiterated at Guggenheim - Defense World
Wedbush Equities Analysts Lift Earnings Estimates for ORIC - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 13.9% on Analyst Upgrade - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $22.00 at JPMorgan Chase & Co. - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives "Buy" Rating from Guggenheim - MarketBeat
Oric Pharmaceuticals announces clinical development plans for ORIC-944, ORIC-114 - TipRanks
ORIC® Pharmaceuticals Announces Focused Registrational - GlobeNewswire
Can ORIC Pharmaceuticals' Extended Cash Runway Fuel Success in Cancer Drug Development? - StockTitan
Wedbush Reduces Earnings Estimates for ORIC Pharmaceuticals - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up Following Earnings Beat - MarketBeat
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):